Ranbaxy Laboratories Limited has recently launched its approved generic formulation of clarithromycin immediate release tablets in the US, according to a press release. Ranbaxy has been given the green signal to manufacture and market Clarithromycin tablets—250 mg and 500 mg under the Ranbaxy label. Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of designated micro-organisms.
The US Food and Drug Administration (FDA), has determined that Ranbaxy's formulation can be expected to have the same therapeutic effect as an equivalent dose of Abbott's Biaxin Filmtab (clarithromycin tablets, USP). Jim Meehan, vice-president of Sales and Marketing for Ranbaxy Pharmaceuticals Inc (RPI) on behalf of the whole team of Ranbaxy has been stated as saying that he is very delighted to market the drug and also mentioned that they have plans to bring the product to the Indian market very soon.